

Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented by Molecule Type (Small Molecule, Large Molecule), By Synthesis (Biotech, Synthetic), By Drug Type (Innovative, Generics), By Workflow (Clinical, Commercial), By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other), By Region, By Competition

<https://marketpublishers.com/r/A100F49974EFEN.html>

Date: February 2024

Pages: 185

Price: US\$ 4,900.00 (Single User License)

ID: A100F49974EFEN

Abstracts

Global Active Pharmaceutical Ingredients CDMO Market was valued at USD 91.98 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 6.10% through 2029. Many pharmaceuticals industry are struggling with the manufacturing of drug substances, and the handling of pharmaceutical applications like manufacturing of the drug, pharmaceutical industry, keeping expenses in mind and also reducing the cost of the drug, higher need for equipment with affordable cost, to keep an eye on all these pharmaceutical industrial factors the Contract Development and manufacturing organization (CDMO) comes in partnership with the pharmaceutical industries to form innovative formulas and products into the market without investing additional expenses or infrastructure to support. The Pharmaceutical CDMO handles the outsourcing of drug substances and works with innovation and development program that occurs before manufacturing one. The Pharmaceutical CDMO is one of the most important factors for the positive substantial growth of the healthcare industry.

Key Market Drivers

Increasing Demand for Customized Drug Development

Pharmaceutical companies often require specialized expertise and technologies to develop and manufacture customized drugs, which may include complex small molecules, biologics, high-potency compounds, or novel formulations. CDMOs with a focus on customization have the necessary knowledge and infrastructure to meet these specific needs, making them invaluable partners for pharmaceutical companies. Customized drug development often involves innovative and unique approaches to drug design and manufacturing. CDMOs can provide pharmaceutical companies with the resources and capabilities to expedite drug development processes, reducing time-to-market for new drugs.

Customized drug development can be resource-intensive, requiring substantial investments in research and development (R&D). Outsourcing to CDMOs allows pharmaceutical companies to access specialized capabilities without the need for substantial in-house investments, thereby reducing overall R&D costs. CDMOs offer scalable manufacturing solutions, allowing pharmaceutical companies to adjust production volumes as needed. This scalability is crucial for customized drugs, as demand can vary widely, from small-batch clinical trials to large-scale commercial production. Customized drug development often involves high levels of technical risk due to the unique nature of the compounds or formulations. By partnering with experienced CDMOs, pharmaceutical companies can mitigate these risks by leveraging the CDMO's expertise and track record in handling similar challenges. CDMOs specializing in customized drug development are well-versed in navigating complex regulatory requirements. They can help ensure that the customized drugs meet all regulatory standards, which is crucial for gaining approval and commercialization.

Growing Biopharmaceuticals Sector

Biopharmaceuticals, which include biologics like monoclonal antibodies, vaccines, and gene therapies, require specialized manufacturing processes. CDMOs with expertise in bioprocessing and biomanufacturing are in high demand to assist pharmaceutical companies in producing these complex and large-molecule drugs. Many pharmaceutical companies, especially smaller or newer entrants in the industry, may not have the in-house expertise or infrastructure for biologics development and manufacturing. They turn to CDMOs to access the necessary resources and skills. Building and maintaining biopharmaceutical manufacturing facilities can be incredibly expensive and time-consuming. Outsourcing to CDMOs allows pharmaceutical companies to reduce capital expenditures, minimize operational costs, and achieve cost-efficiency in biologics

production.

The biopharmaceutical industry often faces fluctuations in demand, particularly for biologics with variable production requirements. CDMOs offer the flexibility to scale up or down production volumes as needed, optimizing resource utilization for pharmaceutical companies. Regulatory agencies have stringent requirements for the manufacturing and quality control of biologics. Established CDMOs have a track record of compliance with these regulations, giving pharmaceutical companies confidence in the quality and safety of their biopharmaceutical products. CDMOs specializing in biologics can expedite the drug development and manufacturing process. Their expertise, infrastructure, and streamlined operations can significantly reduce the time it takes to bring biopharmaceutical products to market, enabling pharmaceutical companies to capture opportunities more quickly.

Rise in Complex Drug Molecules

Complex drug molecules, which include high-potency APIs, biologics, and advanced formulations, require specialized knowledge and capabilities for their development and manufacturing. CDMOs with expertise in handling complex drug molecules become essential partners for pharmaceutical companies seeking to navigate the challenges of these compounds. Complex drug molecules often necessitate the use of advanced technologies and sophisticated manufacturing processes. CDMOs invest in state-of-the-art equipment and infrastructure to accommodate these requirements, making them well-suited to support the development and production of complex drugs. Developing and manufacturing complex drug molecules can be associated with higher technical and regulatory risks. Pharmaceutical companies can mitigate these risks by partnering with experienced CDMOs that have a proven track record of successfully handling complex compounds.

Complex drug molecules frequently face rigorous regulatory scrutiny due to their unique characteristics. CDMOs specializing in complex compounds have established quality assurance systems and compliance protocols to ensure that the products meet regulatory requirements. Developing and maintaining the infrastructure for complex drug manufacturing can be prohibitively expensive. By outsourcing to CDMOs, pharmaceutical companies can reduce capital investments, minimize operational costs, and achieve cost-efficiency in the production of complex drug molecules. CDMOs can tailor their services to the specific needs of pharmaceutical companies developing complex drugs. This customization ensures that the manufacturing processes are optimized for the unique properties and requirements of each compound.

Key Market Challenges

Regulatory Complexities

The pharmaceutical industry is highly regulated, and CDMOs must adhere to a myriad of stringent quality and safety standards. Compliance with these regulations often requires significant investments in infrastructure, personnel, and documentation. The associated compliance costs can reduce profit margins and make it challenging for CDMOs to offer competitive pricing. Regulatory approvals and compliance checks can introduce delays into the drug development and manufacturing process. CDMOs may face prolonged approval processes, inspections, and audits, which can impact project timelines. Pharmaceutical companies may seek faster alternatives, such as in-house manufacturing, to mitigate these delays. Meeting regulatory requirements demands substantial resources, including specialized personnel and extensive documentation. Smaller or newer CDMOs may struggle to allocate the necessary resources, hindering their ability to compete effectively in the market.

The pharmaceutical regulatory landscape varies from one region to another, with differences in standards, documentation, and inspection requirements. CDMOs operating in multiple countries must navigate this complex global regulatory environment, which can be both time-consuming and costly. Regulatory non-compliance can have severe consequences, including product recalls, legal penalties, and damage to a CDMO's reputation. The fear of non-compliance may deter pharmaceutical companies from partnering with CDMOs, especially those without a strong track record of regulatory adherence. Regulatory agencies demand extensive documentation of manufacturing processes, quality control, and product testing. Maintaining accurate and comprehensive records is resource-intensive and can divert CDMO staff from core activities.

Quality Control and Compliance

Ensuring quality and compliance requires significant investments in infrastructure, personnel, and quality control processes. CDMOs must allocate substantial resources to maintain compliance, which can increase operational costs and reduce profit margins. Quality assurance and compliance procedures often involve meticulous documentation, quality control checks, and validation processes. These activities can be time-consuming and may introduce delays into project timelines, potentially frustrating pharmaceutical clients. Regulatory authorities impose strict standards on the

pharmaceutical industry to ensure product safety and efficacy. CDMOs must continuously monitor and adapt to these evolving regulations, which can be complex and demanding.

Non-compliance with quality and regulatory standards can have severe consequences, including product recalls, regulatory fines, and reputational damage. The fear of non-compliance can make pharmaceutical companies cautious about partnering with CDMOs that do not have a strong track record in this regard. Maintaining comprehensive documentation for every aspect of drug development and manufacturing is a fundamental requirement for compliance. The extensive paperwork and record-keeping can be resource-intensive and divert CDMO staff from core tasks. The global pharmaceutical market encompasses a range of regulatory bodies, each with its own set of requirements. CDMOs operating on a global scale must navigate the varying compliance standards of different regions, adding complexity to their operations.

Key Market Trends

Biologics and Complex Molecules Dominance

Biologics and complex molecules often require specialized expertise and infrastructure for their development and manufacturing. CDMOs with capabilities in bioprocessing, cell culture, and large-scale fermentation are in high demand to support the production of these intricate compounds. To meet the demands of biologics and complex molecules, CDMOs are investing in state-of-the-art technologies and equipment. This includes bioreactors, chromatography systems, and analytical tools specifically designed for bioprocessing and characterization. The growing dominance of biologics has led to an expansion of manufacturing capacity for CDMOs in this sector. This includes the construction of dedicated biologics facilities equipped to handle large-scale production.

CDMOs are increasing their research and development efforts to stay at the forefront of biologics and complex molecule technologies. This commitment to innovation allows CDMOs to offer cutting-edge solutions and attract pharmaceutical companies looking to develop novel therapies. The demand for biologics is global, with markets spanning multiple regions. CDMOs with a global presence can better serve pharmaceutical clients by providing access to diverse markets and ensuring local regulatory compliance. Biologics and complex molecules often require customized manufacturing processes. CDMOs offer flexible and tailored solutions to meet the specific needs of each client and their unique compounds.

Cell and Gene Therapies

Cell and gene therapies require highly specialized expertise and infrastructure for development and manufacturing. CDMOs with capabilities in cell culture, viral vector production, and gene editing technologies are in high demand to support these innovative therapies. CDMOs are investing heavily in cutting-edge technologies and facilities tailored for cell and gene therapy production. This includes state-of-the-art cleanroom environments, bioreactors, and cryopreservation systems designed to meet the unique requirements of these therapies. The growth in demand for cell and gene therapies has prompted CDMOs to expand their manufacturing capacity in this sector. This includes constructing dedicated facilities to handle the specialized processes involved in the production of these therapies.

The regulatory landscape for cell and gene therapies is complex and evolving. CDMOs specializing in these therapies possess in-depth knowledge of regulatory requirements, helping pharmaceutical companies navigate the approval process and ensure compliance. Cell and gene therapies come with inherent technical and regulatory risks. Pharmaceutical companies mitigate these risks by partnering with CDMOs experienced in managing the complexities and challenges associated with these therapies. The demand for cell and gene therapies extends worldwide, necessitating a global presence for CDMOs to provide access to diverse markets and ensure compliance with local regulatory authorities.

Segmental Insights

Synthesis Insights

Based on the Synthesis, the biotech segment is anticipated to witness substantial market growth throughout the forecast period. Biologics, including monoclonal antibodies, vaccines, and biosimilars, represent a substantial portion of the CDMO market. CDMOs with expertise in bioprocessing and large-scale fermentation are in high demand to support the development and manufacturing of these complex molecules. The rapid growth of cell and gene therapies is transforming the pharmaceutical industry. CDMOs are establishing specialized facilities and capabilities to meet the unique requirements of these therapies, including cell culture, viral vector production, and gene editing technologies. Oncology drugs, including targeted therapies and immunotherapies, are a major driver of Active Pharmaceutical Ingredients CDMO market growth. As cancer treatments become more personalized, CDMOs are offering specialized services for the development and production of oncology therapeutics.

The biotech sector is increasingly focused on rare diseases, leading to a growing demand for CDMOs specializing in the development and manufacturing of orphan drugs. These drugs often require unique formulations and production processes. As research in neurodegenerative disorders like Alzheimer's and Parkinson's disease advances, CDMOs are providing support for the development of innovative therapies targeting these conditions. This segment is poised for growth as more therapies progress through clinical trials. The development of vaccines, antiviral drugs, and treatments for infectious diseases remains a critical area of biotech research. CDMOs are contributing to the manufacturing of vaccines and therapies for infectious diseases, particularly in response to global health crises like pandemics.

Drug Type Insights

Based on the Drug Type segment, the generics drugs segment has been the dominant force in the market. Generic drugs are typically produced at a lower cost compared to their branded counterparts. CDMOs specializing in generics can leverage efficient and cost-effective manufacturing processes to meet the high demand for these products.

Increased Demand: The rising demand for generic drugs, driven by the need for affordable healthcare solutions, presents growth opportunities for CDMOs. As pharmaceutical companies seek to expand their generic drug portfolios, they often turn to CDMOs to access cost-efficient manufacturing capabilities. Generic drugs encompass a wide range of therapeutic categories, including cardiovascular, central nervous system, and respiratory medications. This diversity offers CDMOs opportunities to work on a variety of drug formulations and compounds.

Some generic drugs, particularly complex generics such as biosimilars and specialty generics, require advanced manufacturing technologies and expertise. CDMOs with capabilities in bioprocessing, sterile manufacturing, and complex dosage forms are in demand to support the development and production of these products. Ensuring regulatory compliance is crucial in the generic drug industry. CDMOs with a strong track record of meeting regulatory standards and navigating the complexities of abbreviated new drug applications (ANDAs) are sought after by pharmaceutical companies. The global reach of generic drugs creates opportunities for CDMOs with a presence in multiple regions. These CDMOs can help pharmaceutical companies access diverse markets and meet local regulatory requirements.

Regional Insights

North America, specifically the Active Pharmaceutical Ingredients CDMO Market, dominated the market in 2023, primarily due to North America, particularly the United States, represents one of the largest pharmaceutical markets in the world. The region's prominence in pharmaceutical research, development, and manufacturing makes it a primary driver of global API CDMO market growth. Pharmaceutical companies in North America increasingly rely on CDMOs to outsource various stages of drug development and manufacturing. The growing demand for CDMO services is driven by factors such as cost-efficiency, regulatory expertise, and access to specialized technologies. North America is a global hub for biotechnology and pharmaceutical research and innovation. This concentration of biotech and pharma companies creates a thriving ecosystem for CDMOs to collaborate and provide essential support in developing novel drug compounds.

North America is a leader in the development of biologics and complex molecules, including monoclonal antibodies, gene therapies, and biosimilars. CDMOs with expertise in these areas are well-positioned to serve the region's biopharmaceutical companies. North America has stringent regulatory requirements for drug development and manufacturing. CDMOs operating in the region must maintain a deep understanding of regulatory standards and demonstrate compliance, making them valuable partners for pharmaceutical companies navigating this complex landscape. North American pharmaceutical companies often form strategic alliances with CDMOs to expedite drug development and access specialized expertise. These collaborations drive growth in the Active Pharmaceutical Ingredients CDMO market as they tap into the region's extensive pharmaceutical infrastructure.

Key Market Players

Cambrex Corporation

Patheon (Thermo Fisher Scientific Inc.)

Recipharm AB

CordenPharma International

Samsung Biologics

Lonza Group

Siegfried

Piramal Pharma Solutions

AbbVie Inc.

Catalent Inc.

Report Scope:

In this report, the Global Active Pharmaceutical Ingredients CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Active Pharmaceutical Ingredients CDMO Market, By Molecule Type:

- o Small Molecule
- o Large Molecule

Active Pharmaceutical Ingredients CDMO Market, By Synthesis:

- o Biotech
- o Synthetic

Active Pharmaceutical Ingredients CDMO Market, By Drug Type:

- o Innovative
- o Generics

Active Pharmaceutical Ingredients CDMO Market, By Workflow:

- o Clinical

- o Commercial

Active Pharmaceutical Ingredients CDMO Market, By Application:

- o Cardiology

- o Oncology

- o Ophthalmology

- o Neurology

- o Orthopedic

- o Other

Active Pharmaceutical Ingredients CDMO Market, By Region:

- o North America

- ? United States

- ? Canada

- ? Mexico

- o Europe

- ? France

- ? United Kingdom

- ? Italy

- ? Germany

? Spain

o Asia-Pacific

? China

? India

? Japan

? Australia

South Korea

o South America

Brazil

Argentina

Colombia

Middle East & Africa

? South Africa

? Saudi Arabia

? UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Active Pharmaceutical Ingredients CDMO Market.

Available Customizations:

Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast...

Global Active Pharmaceutical Ingredients CDMO market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

- 1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Molecule Type (Small Molecule, Large Molecule)
 - 5.2.2. By Synthesis (Biotech, Synthetic)
 - 5.2.3. By Drug Type (Innovative, Generics)
 - 5.2.4. By Workflow (Clinical, Commercial)

5.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)

5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

5.2.7. By Company (2023)

5.3. Market Map

5.3.1 By Molecule Type

5.3.2 By Synthesis

5.3.3 By Drug Type

5.3.4 By Workflow

5.3.5 By Application

5.3.6 By Region

6. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Molecule Type (Small Molecule, Large Molecule)

6.2.2. By Synthesis (Biotech, Synthetic)

6.2.3. By Drug Type (Innovative, Generics)

6.2.4. By Workflow (Clinical, Commercial)

6.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)

6.2.6. By Country

6.3. North America: Country Analysis

6.3.1. United States Active Pharmaceutical Ingredients CDMO Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Molecule Type

6.3.1.2.2. By Synthesis

6.3.1.2.3. By Drug Type

6.3.1.2.4. By Workflow

6.3.1.2.5. By Application

6.3.2. Canada Active Pharmaceutical Ingredients CDMO Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Molecule Type

6.3.2.2.2. By Synthesis

6.3.2.2.3. By Drug Type

6.3.2.2.4. By Workflow

6.3.2.2.5. By Application

6.3.3. Mexico Active Pharmaceutical Ingredients CDMO Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Molecule Type

6.3.3.2.2. By Synthesis

6.3.3.2.3. By Drug Type

6.3.3.2.4. By Workflow

6.3.3.2.5. By Application

7. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Molecule Type (Small Molecule, Large Molecule)

7.2.2. By Synthesis (Biotech, Synthetic)

7.2.3. By Drug Type (Innovative, Generics)

7.2.4. By Workflow (Clinical, Commercial)

7.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)

7.2.6. By Country

7.3. Europe: Country Analysis

7.3.1. France Active Pharmaceutical Ingredients CDMO Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Molecule Type

7.3.1.2.2. By Synthesis

7.3.1.2.3. By Drug Type

7.3.1.2.4. By Workflow

7.3.1.2.5. By Application

7.3.2. Germany Active Pharmaceutical Ingredients CDMO Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Molecule Type

7.3.2.2.2. By Synthesis

7.3.2.2.3. By Drug Type

7.3.2.2.4. By Workflow

7.3.2.2.5. By Application

7.3.3. United Kingdom Active Pharmaceutical Ingredients CDMO Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Molecule Type

7.3.3.2.2. By Synthesis

7.3.3.2.3. By Drug Type

7.3.3.2.4. By Workflow

7.3.3.2.5. By Application

7.3.4. Italy Active Pharmaceutical Ingredients CDMO Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Molecule Type

7.3.4.2.2. By Synthesis

7.3.4.2.3. By Drug Type

7.3.4.2.4. By Workflow

7.3.4.2.5. By Application

7.3.5. Spain Active Pharmaceutical Ingredients CDMO Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Molecule Type

7.3.5.2.2. By Synthesis

7.3.5.2.3. By Drug Type

7.3.5.2.4. By Workflow

7.3.5.2.5. By Application

8. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Molecule Type (Small Molecule, Large Molecule)

8.2.2. By Synthesis (Biotech, Synthetic)

8.2.3. By Drug Type (Innovative, Generics)

8.2.4. By Workflow (Clinical, Commercial)

8.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)

8.2.6. By Country

8.3. Asia-Pacific: Country Analysis

8.3.1. China Active Pharmaceutical Ingredients CDMO Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Molecule Type

8.3.1.2.2. By Synthesis

8.3.1.2.3. By Drug Type

8.3.1.2.4. By Workflow

8.3.1.2.5. By Application

8.3.2. India Active Pharmaceutical Ingredients CDMO Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Molecule Type

8.3.2.2.2. By Synthesis

8.3.2.2.3. By Drug Type

8.3.2.2.4. By Workflow

8.3.2.2.5. By Application

8.3.3. Japan Active Pharmaceutical Ingredients CDMO Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Molecule Type

8.3.3.2.2. By Synthesis

8.3.3.2.3. By Drug Type

8.3.3.2.4. By Workflow

8.3.3.2.5. By Application

8.3.4. South Korea Active Pharmaceutical Ingredients CDMO Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Molecule Type

8.3.4.2.2. By Synthesis

8.3.4.2.3. By Drug Type

8.3.4.2.4. By Workflow

8.3.4.2.5. By Application

8.3.5. Australia Active Pharmaceutical Ingredients CDMO Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Molecule Type

8.3.5.2.2. By Synthesis

8.3.5.2.3. By Drug Type

8.3.5.2.4. By Workflow

8.3.5.2.5. By Application

9. SOUTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Molecule Type (Small Molecule, Large Molecule)

9.2.2. By Synthesis (Biotech, Synthetic)

9.2.3. By Drug Type (Innovative, Generics)

9.2.4. By Workflow (Clinical, Commercial)

9.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)

9.2.6. By Country

9.3. South America: Country Analysis

9.3.1. Brazil Active Pharmaceutical Ingredients CDMO Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Molecule Type

9.3.1.2.2. By Synthesis

- 9.3.1.2.3. By Drug Type
- 9.3.1.2.4. By Workflow
- 9.3.1.2.5. By Application
- 9.3.2. Argentina Active Pharmaceutical Ingredients CDMO Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Molecule Type
 - 9.3.2.2.2. By Synthesis
 - 9.3.2.2.3. By Drug Type
 - 9.3.2.2.4. By Workflow
 - 9.3.2.2.5. By Application
- 9.3.3. Colombia Active Pharmaceutical Ingredients CDMO Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Molecule Type
 - 9.3.3.2.2. By Synthesis
 - 9.3.3.2.3. By Drug Type
 - 9.3.3.2.4. By Workflow
 - 9.3.3.2.5. By Application

10. MIDDLE EAST AND AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Molecule Type (Small Molecule, Large Molecule)
 - 10.2.2. By Synthesis (Biotech, Synthetic)
 - 10.2.3. By Drug Type (Innovative, Generics)
 - 10.2.4. By Workflow (Clinical, Commercial)
 - 10.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
 - 10.2.6. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Active Pharmaceutical Ingredients CDMO Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Molecule Type

10.3.1.2.2. By Synthesis

10.3.1.2.3. By Drug Type

10.3.1.2.4. By Workflow

10.3.1.2.5. By Application

10.3.2. Saudi Arabia Active Pharmaceutical Ingredients CDMO Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Molecule Type

10.3.2.2.2. By Synthesis

10.3.2.2.3. By Drug Type

10.3.2.2.4. By Workflow

10.3.2.2.5. By Application

10.3.3. UAE Active Pharmaceutical Ingredients CDMO Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Molecule Type

10.3.3.2.2. By Synthesis

10.3.3.2.3. By Drug Type

10.3.3.2.4. By Workflow

10.3.3.2.5. By Application

11. MARKET DYNAMICS

11.1. Drivers

11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Recent Development

12.2. Mergers & Acquisitions

12.3. Product Launches

13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

- 15.1. Cambrex Corporation
 - 15.1.1. Business Overview
 - 15.1.2. Product Offerings
 - 15.1.3. Recent Developments
 - 15.1.4. Financials (As Reported)
 - 15.1.5. Key Personnel
 - 15.1.6. SWOT Analysis
- 15.2. Patheon (Thermo Fisher Scientific Inc.)
 - 15.2.1. Business Overview
 - 15.2.2. Product Offerings
 - 15.2.3. Recent Developments
 - 15.2.4. Financials (As Reported)
 - 15.2.5. Key Personnel
 - 15.2.6. SWOT Analysis
- 15.3. Recipharm AB
 - 15.3.1. Business Overview
 - 15.3.2. Product Offerings
 - 15.3.3. Recent Developments
 - 15.3.4. Financials (As Reported)
 - 15.3.5. Key Personnel
 - 15.3.6. SWOT Analysis
- 15.4. CordenPharma International
 - 15.4.1. Business Overview
 - 15.4.2. Product Offerings
 - 15.4.3. Recent Developments
 - 15.4.4. Financials (As Reported)
 - 15.4.5. Key Personnel
 - 15.4.6. SWOT Analysis
- 15.5. Samsung Biologics

- 15.5.1. Business Overview
- 15.5.2. Product Offerings
- 15.5.3. Recent Developments
- 15.5.4. Financials (As Reported)
- 15.5.5. Key Personnel
- 15.5.6. SWOT Analysis
- 15.6. Lonza Group
 - 15.6.1. Business Overview
 - 15.6.2. Product Offerings
 - 15.6.3. Recent Developments
 - 15.6.4. Financials (As Reported)
 - 15.6.5. Key Personnel
 - 15.6.6. SWOT Analysis
- 15.7. Siegfried
 - 15.7.1. Business Overview
 - 15.7.2. Product Offerings
 - 15.7.3. Recent Developments
 - 15.7.4. Financials (As Reported)
 - 15.7.5. Key Personnel
 - 15.7.6. SWOT Analysis
- 15.8. Piramal Pharma Solutions
 - 15.8.1. Business Overview
 - 15.8.2. Product Offerings
 - 15.8.3. Recent Developments
 - 15.8.4. Financials (As Reported)
 - 15.8.5. Key Personnel
 - 15.8.6. SWOT Analysis
- 15.9. AbbVie Inc.
 - 15.9.1. Business Overview
 - 15.9.2. Product Offerings
 - 15.9.3. Recent Developments
 - 15.9.4. Financials (As Reported)
 - 15.9.5. Key Personnel
 - 15.9.6. SWOT Analysis
- 15.10. Catalent Inc.
 - 15.10.1. Business Overview
 - 15.10.2. Product Offerings
 - 15.10.3. Recent Developments
 - 15.10.4. Financials (As Reported)

15.10.5. Key Personnel

15.10.6. SWOT Analysis

16. STRATEGIC RECOMMENDATIONS

I would like to order

Product name: Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented by Molecule Type (Small Molecule, Large Molecule), By Synthesis (Biotech, Synthetic), By Drug Type (Innovative, Generics), By Workflow (Clinical, Commercial), By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other), By Region, By Competition

Product link: <https://marketpublishers.com/r/A100F49974EFEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A100F49974EFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970